Cytokinetics Ends Tirasemtiv Program After Potential ALS Therapy Fails at Trial Goals

Cytokinetics Ends Tirasemtiv Program After Potential ALS Therapy Fails at Trial Goals

Expressing “profound disappointment” with tirasemtiv — their lead candidate for amyotrophic lateral sclerosis (ALS) — officials at Cytokinetics have ended development of the once-promising therapy.

Robert I. Blum, president and chief executive officer of the San Francisco-based biotech, announced negative results for VITALITY-ALS (NCT02496767) after tirasemtiv, a fast skeletal muscle troponin activator, failed to meet the primary endpoint or any of the secondary endpoints of the Phase 3 clinical trial.

Mainly, tirasemtiv failed to demonstrate greater improvements in slow vital capacity (SVC), a key measure of lung capacity, over a 24-week period compared to placebo. In addition, ALS patients taking the drug did no better than those on placebo when it came to the 48-week secondary endpoints assessing functional ability and muscle strength.

“This is a disappointing day for patients with ALS and their caregivers who are in desperate need of new therapies,” Blum said in a Nov. 21 conference call. “All of us at Cytokinetics have been dedicated so diligently for so many years to find a potential new medicine for patients with ALS. We also recognize this is a disappointing day for shareholders and others who shared our hope for potential positive results.”

Issues included dizziness, light-headedness and nausea, which were also the main side effects seen in the Phase 2 BENEFIT-ALS trial (NCT01709149), the company said. Most tolerability issues were due to off-target effects of the drug on the brain, since tirasemtiv crosses the blood-brain barrier. This physical barrier shields the brain from the overall blood circulation, tightly regulating molecules that can enter the brain from the bloodstream, including drugs.

Cytokinetics is now pinning its hopes on a second fast skeletal muscle activator in its pipeline, CK-2127107, in collaboration with Japan’s Astellas Pharma.

“Based on previous Phase 1 clinical studies, we believe CK-2127107 will be better tolerated and potentially more effective than tirasemtiv in patients with ALS,” said Blum, who expects to release Phase 2 trial (NCT03160898) results sometime in 2018. CK-2127107, researchers believe, is unable to cross the blood-brain barrier, a marked difference from tirasemtiv.

Three such trials are now underway, in ALS patients and those with spinal muscular atrophy (NCT02644668) and chronic obstructive pulmonary disease (NCT02662582). Cytokinetics is also studying CK-2127107 in a Phase 1b trial of elderly subjects with limited mobility (NCT03065959).

“We believe we did the right thing to test the hypothesis that tirasemtiv may potentially reduce the decline in SVC [slow vital capacity] in patients afflicted with ALS, by seeking to confirm the results of BENEFIT-ALS [the last of four Phase 2 trials of tirasemtiv],” he said. “We designed VITALITY-ALS to ask key scientific and clinical questions.”

VITALITY enrolled 744 ALS patients at 81 investigative centers in 11 countries, said Dr. Fady I. Malik, the company’s executive vice president of research and development.

Patients received 125 mg of tirasemtiv twice a day for two weeks, and were then randomly assigned to one of three tirasemtiv doses — 125 mg, 375 mg or 500 mg — twice a day, or placebo.

“There were no new safety or tolerability findings, and serious adverse events were similar to placebo,” he said. “More patients discontinued double-blind treatments of tirasemtiv than placebo, however. We believe poor tolerability of tirasemtiv may have contributed to these results.”

Cytokinetics will present final results of its study Dec. 8 at the 28th ALS/MND Symposium in Boston.

“Until then, we believe the results are clear, and we’ve concluded that the tolerability profile interferes with our ability to meaningfully demonstrate a therapeutic signal,” Malik said. “The right thing to do now is suspend further development of tirasemtiv.”

Dr. Andrew Wolff, chief medical officer at Cytokinetics, cited “higher than expected dropouts,” as well as “an excess of non-serious adverse effects that contributed to more early terminations.” In all, tirasemtiv had been studied in clinical trials that enrolled more than 1,000 people around the world.

“We conduct trials like this to generate and test scientific and clinical hypotheses, and we know how much patients and their caregivers were hoping for a different outcome. So were we,” Blum said. “These results only reinforce our resolve, however, to keep up the fight alongside you.”

The Washington-based ALS Association said it, too, is saddened by the results of the VITALITY-ALS trial.

“We are grateful that Cytokinetics has already expressed its commitment to finding new therapies for people with ALS and hopeful that its next treatment, which is currently in clinical trials, will be successful,” the nonprofit organization said in a brief statement. “We thank Cytokinetics for its unwavering support of the ALS community.”

12 comments

  1. Charlie says:

    The abject failure of Tirasemtiv gives rise to two difficulties. Apart from the prospect of a possible treatment for pALS now being classed as ‘no-go’ we have the technical situation of the methodology of its suggested efficacy being shown to be a ‘no-go.’
    That will be more than a simple head-scratcher for research going down that particular route way.

  2. sal says:

    For God’s sake stop giving placebo to als patients. If your drug is good, it will show results. Don’t waste precious time with placebo. Think out side the box. Be innovative. We don’t have years to wait.

    • Charlie says:

      About CK-2127107

      In preclinical studies, CK-107 has been shown to slow the rate of calcium release from the regulatory troponin complex of fast skeletal muscle fibers, thus increasing the sensitivity of the skeletal muscle to calcium, which results in an increase in skeletal muscle force production in response to neuronal input and which also delays the onset and reduces the magnitude of fatigue during repetitive muscle stimulation. Thus, CK-107 may improve muscle function and physical performance in people with COPD. In collaboration with Astellas, Cytokinetics is conducting a Phase 2 clinical trial of CK-107 which is designed to assess the effect of CK-107 on measures of muscle function in both ambulatory and non-ambulatory patients with SMA, a severe, genetic neuromuscular disease that leads to debilitating muscle function and progressive, often fatal, muscle weakness.

  3. Douglas says:

    I am one who was in the extended trial and I tolerated the drug very well. One of a very small group I now see. I have a friend who left the trial after 17 months because she couldn’t tolerate some of the side effects. I have 2 other friends who tried but didn’t even qualify. I am proud that I go to a support group where we had almost 40% try to be in this trial. One of them tried 2 other trials after waiting the required month to “clean out” the previous trial drug.

    Disappointed, yes. Abject failure, no. They learned many important things because of this failure to meet their expected goals. This is what trials are for. I think they could change the qualifications for inclusion into a trial. I do have a slower progressing ALS and will be coming up on 4 years since diagnosis early next year. I feel like I could be a valuable participant in another trial but won’t even be able to try to qualify for another trial. In fact, it looks like they are tightening the qualifications instead of opening them to a potentially larger population.

    I hope and pray for a treatment and eventually a cure. Over the past 2 years, I have met scores of scientists who are passionately working on finding a cure. There are many more trials today than ever before. These things give me hope that we are close.

    I mostly agree with Sal’s post about placebos, but you still have to have it tested that way, but I would think a shorter timeframe composted to placebo before all trial subjects being given the drug.

  4. Charlie says:

    ‘ALS is complex: It’s not just one disease, it’s many diseases, and we haven’t been able to make a sufficient impact on it yet,” said Dr. Durham. “I’m looking forward to finally getting a clear answer on whether we can use understandings about heat shock proteins as a basis for an effective treatment for ALS.”

  5. Charlie says:

    “I hope and pray for a treatment and eventually a cure.”
    I think we all do.
    I pray to science for a treatment and a cure, because to pray to the other usual entity has shown very clearly that he is not in the slightest bit interested.

Leave a Comment

Your email address will not be published. Required fields are marked *